A patient with a history of chronic asthma arrives for their scheduled omalizumab injection. The nurse reviews the patient's medical history and notices that they have a reported allergy to peanuts. What is the most appropriate nursing action?

Choice A rationale Administering omalizumab despite a reported allergy to peanuts is potentially unsafe because omalizumab has a black box warning for anaphylaxis, which can be life-threatening. While the peanut allergy may not directly contraindicate omalizumab, it suggests a heightened risk for severe allergic reactions due to atopy. Prudence dictates consulting the provider for risk assessment, skin testing, or alternative treatments, prioritizing patient safety before injection. Choice B rationale Omalizumab carries a risk of anaphylaxis, which can occur after any dose, including the first. A documented allergy, particularly to a common and potent allergen like peanuts, indicates a predisposition to hypersensitivity reactions (atopy). The most appropriate and safest nursing action is to withhold the injection and notify the healthcare provider to evaluate the risk and determine if the medication is still indicated or if precautions, such as desensitization or alternative therapy, are required. Choice C rationale Asking about recent anaphylaxis symptoms does not mitigate the potential risk of a future, severe reaction to omalizumab, which has a boxed warning for anaphylaxis. While a history of severe allergies is pertinent, the immediate safety concern is the risk of a severe hypersensitivity reaction to the drug itself. The nurse must address the reported allergy and the drug's known risks before proceeding with administration. Choice D rationale While ensuring an EpiPen is available is a precautionary measure for any patient receiving omalizumab due to the risk of anaphylaxis, it does not address the underlying concern of the documented peanut allergy, which might increase the patient's overall allergic predisposition. The nurse's first action must be to ensure the drug is safe to administer, which means consulting the provider about the allergy before administration.